Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Passenger deletions generate therapeutic vulnerabilities in cancer.

Muller FL, Colla S, Aquilanti E, Manzo VE, Genovese G, Lee J, Eisenson D, Narurkar R, Deng P, Nezi L, Lee MA, Hu B, Hu J, Sahin E, Ong D, Fletcher-Sananikone E, Ho D, Kwong L, Brennan C, Wang YA, Chin L, DePinho RA.

Nature. 2012 Aug 16;488(7411):337-42. doi: 10.1038/nature11331. Erratum in: Nature. 2015 Sep 10;525(7568):278.

2.

Comprehensive analysis of glycolytic enzymes as therapeutic targets in the treatment of glioblastoma.

Sanzey M, Abdul Rahim SA, Oudin A, Dirkse A, Kaoma T, Vallar L, Herold-Mende C, Bjerkvig R, Golebiewska A, Niclou SP.

PLoS One. 2015 May 1;10(5):e0123544. doi: 10.1371/journal.pone.0123544.

3.

Enolase-1 is a therapeutic target in endometrial carcinoma.

Zhao M, Fang W, Wang Y, Guo S, Shu L, Wang L, Chen Y, Fu Q, Liu Y, Hua S, Fan Y, Liu Y, Deng X, Luo R, Mei Z, Jiang Q, Liu Z.

Oncotarget. 2015 Jun 20;6(17):15610-27.

4.

Cancer: Exploiting collateral damage.

Lehner B, Park S.

Nature. 2012 Aug 16;488(7411):284-5. doi: 10.1038/488284a. No abstract available.

PMID:
22895327
5.

Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.

Stangeland B, Mughal AA, Grieg Z, Sandberg CJ, Joel M, Nygård S, Meling T, Murrell W, Vik Mo EO, Langmoen IA.

Oncotarget. 2015 Sep 22;6(28):26192-215. doi: 10.18632/oncotarget.4613.

6.

Up-Regulation of ENO1 by HIF-1α in Retinal Pigment Epithelial Cells after Hypoxic Challenge Is Not Involved in the Regulation of VEGF Secretion.

Zheng F, Jang WC, Fung FK, Lo AC, Wong IY.

PLoS One. 2016 Feb 16;11(2):e0147961. doi: 10.1371/journal.pone.0147961.

7.

Introduction of in vitro transcribed ENO1 mRNA into neuroblastoma cells induces cell death.

Ejeskär K, Krona C, Carén H, Zaibak F, Li L, Martinsson T, Ioannou PA.

BMC Cancer. 2005 Dec 16;5:161.

8.

Alpha-enolase promotes cell glycolysis, growth, migration, and invasion in non-small cell lung cancer through FAK-mediated PI3K/AKT pathway.

Fu QF, Liu Y, Fan Y, Hua SN, Qu HY, Dong SW, Li RL, Zhao MY, Zhen Y, Yu XL, Chen YY, Luo RC, Li R, Li LB, Deng XJ, Fang WY, Liu Z, Song X.

J Hematol Oncol. 2015 Mar 8;8:22. doi: 10.1186/s13045-015-0117-5.

9.

Targeting of surface alpha-enolase inhibits the invasiveness of pancreatic cancer cells.

Principe M, Ceruti P, Shih NY, Chattaragada MS, Rolla S, Conti L, Bestagno M, Zentilin L, Yang SH, Migliorini P, Cappello P, Burrone O, Novelli F.

Oncotarget. 2015 May 10;6(13):11098-113.

10.
11.

ENO1, a potential prognostic head and neck cancer marker, promotes transformation partly via chemokine CCL20 induction.

Tsai ST, Chien IH, Shen WH, Kuo YZ, Jin YT, Wong TY, Hsiao JR, Wang HP, Shih NY, Wu LW.

Eur J Cancer. 2010 Jun;46(9):1712-23. doi: 10.1016/j.ejca.2010.03.018.

PMID:
20435467
12.

The Jak2 small molecule inhibitor, G6, reduces the tumorigenic potential of T98G glioblastoma cells in vitro and in vivo.

Baskin R, Park SO, Keserű GM, Bisht KS, Wamsley HL, Sayeski PP.

PLoS One. 2014 Aug 27;9(8):e105568. doi: 10.1371/journal.pone.0105568.

13.

MiR-449a exerts tumor-suppressive functions in human glioblastoma by targeting Myc-associated zinc-finger protein.

Yao Y, Ma J, Xue Y, Wang P, Li Z, Li Z, Hu Y, Shang X, Liu Y.

Mol Oncol. 2015 Mar;9(3):640-56. doi: 10.1016/j.molonc.2014.11.003.

14.

Identification of ATP citrate lyase as a positive regulator of glycolytic function in glioblastomas.

Beckner ME, Fellows-Mayle W, Zhang Z, Agostino NR, Kant JA, Day BW, Pollack IF.

Int J Cancer. 2010 May 15;126(10):2282-95. doi: 10.1002/ijc.24918.

15.

Inhibition of LSD1 sensitizes glioblastoma cells to histone deacetylase inhibitors.

Singh MM, Manton CA, Bhat KP, Tsai WW, Aldape K, Barton MC, Chandra J.

Neuro Oncol. 2011 Aug;13(8):894-903. doi: 10.1093/neuonc/nor049.

16.

miR-34a functions as a tumor suppressor modulating EGFR in glioblastoma multiforme.

Yin D, Ogawa S, Kawamata N, Leiter A, Ham M, Li D, Doan NB, Said JW, Black KL, Phillip Koeffler H.

Oncogene. 2013 Feb 28;32(9):1155-63. doi: 10.1038/onc.2012.132.

17.

Role of enolase-1 in response to hypoxia in breast cancer: exploring the mechanisms of action.

Gao J, Zhao R, Xue Y, Niu Z, Cui K, Yu F, Zhang B, Li S.

Oncol Rep. 2013 Apr;29(4):1322-32. doi: 10.3892/or.2013.2269.

PMID:
23381546
18.

KIAA1797/FOCAD encodes a novel focal adhesion protein with tumour suppressor function in gliomas.

Brockschmidt A, Trost D, Peterziel H, Zimmermann K, Ehrler M, Grassmann H, Pfenning PN, Waha A, Wohlleber D, Brockschmidt FF, Jugold M, Hoischen A, Kalla C, Waha A, Seifert G, Knolle PA, Latz E, Hans VH, Wick W, Pfeifer A, Angel P, Weber RG.

Brain. 2012 Apr;135(Pt 4):1027-41. doi: 10.1093/brain/aws045.

19.

Serine/threonine kinase 17A is a novel candidate for therapeutic targeting in glioblastoma.

Mao P, Hever-Jardine MP, Rahme GJ, Yang E, Tam J, Kodali A, Biswal B, Fadul CE, Gaur A, Israel MA, Spinella MJ.

PLoS One. 2013 Nov 28;8(11):e81803. doi: 10.1371/journal.pone.0081803.

20.

Functional genomics to explore cancer cell vulnerabilities.

Kahle KT, Kozono D, Ng K, Hsieh G, Zinn PO, Nitta M, Chen CC.

Neurosurg Focus. 2010 Jan;28(1):E5. doi: 10.3171/2009.10.FOCUS09212.

PMID:
20043720
Items per page

Supplemental Content

Support Center